Supernus Pharmaceuticals (LTS:0LB2) YoY EPS Growth: -352.50% (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0LB2 Supernus Pharmaceuticals Inc LTS:0LB2
85 GF Score
Price $41.45
GF Value $43.67
Valuation Fairly Valued
! 1 Warning Sign
View Full Analysis

What is Supernus Pharmaceuticals YoY EPS Growth?

Supernus Pharmaceuticals LTS:0LB2 -0.66% 85 YoY EPS Growth is -352.50% as of Jun. 2026. GuruFocus rates LTS:0LB2 with a GF Score™ of 85/100 and a GF Value™ of $43.67 (Fairly Valued). The stock has 1 warning sign investors should review.

YoY EPS Growth is the percentage change of Earnings per Share (Diluted) over the past twelve months. Supernus Pharmaceuticals's YoY EPS Growth for the quarter that ended in Jun. 2026 was -352.50%.

Supernus Pharmaceuticals's Earnings per Share (Diluted) for the three months ended in Jun. 2026 was $-1.01.

Supernus Pharmaceuticals YoY EPS Growth Historical Data

* Premium members only.

The historical data trend for Supernus Pharmaceuticals's YoY EPS Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Supernus Pharmaceuticals YoY EPS Growth Chart

Supernus Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
YoY EPS Growth
Get a 7-Day Free Trial Premium Member Only Premium Member Only -58.47 6.12 -98.08 6,500.00 -151.52

Supernus Pharmaceuticals Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
YoY EPS Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 11.11 -215.94 -125.93 80.95 -352.50
LTS:0LB2
85GF Score
Supernus Pharmaceuticals Inc LTS:0LB2
YoY EPS Growth is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Supernus Pharmaceuticals YoY EPS Growth Calculation

YoY EPS Growth is the percentage change of Earnings per Share (Diluted) over the past twelve months.

Supernus Pharmaceuticals's YoY EPS Growth for the fiscal year that ended in Dec. 2025 is calculated as:

YoY EPS Growth (A: Dec. 2025 )
=(Earnings per Share (Diluted) (A: Dec. 2025 )-Earnings per Share (Diluted) (A: Dec. 2024 ))/ | Earnings per Share (Diluted) (A: Dec. 2024 ) |
=(-0.68-1.32)/ | 1.32 |
=-151.52 %

Supernus Pharmaceuticals's YoY EPS Growth for the quarter that ended in Jun. 2026 is calculated as:

YoY EPS Growth (Q: Jun. 2026 )
=(Earnings per Share (Diluted) (Q: Jun. 2026 )-Earnings per Share (Diluted) (Q: Jun. 2025 )) / | Earnings per Share (Diluted) (Q: Jun. 2025 )) |
=(-1.01-0.4)/ | 0.4 |
=-352.50 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about YoY EPS Growth →
What does a YoY EPS Growth of -352.50% mean?
Supernus Pharmaceuticals (LTS:0LB2) has a YoY EPS Growth of -352.50% as of Jun. 2026. YoY EPS Growth is the percentage change of EPS over the past 12-month. View historical data for Supernus Pharmaceuticals and its competitors.
Is Supernus Pharmaceuticals' YoY EPS Growth too high?
Supernus Pharmaceuticals' current YoY EPS Growth is -352.50%. Overall, Supernus Pharmaceuticals has a GF Score™ of 85/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Supernus Pharmaceuticals' YoY EPS Growth compare to BCRX and PBH?
Supernus Pharmaceuticals' YoY EPS Growth of -352.50% can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good YoY EPS Growth for a Drug Manufacturers company?
A good YoY EPS Growth depends on the Drug Manufacturers industry context. However, YoY EPS Growth should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high YoY EPS Growth mean?
A high YoY EPS Growth can signal that a stock is expensive relative to its fundamentals. YoY EPS Growth is the percentage change of EPS over the past 12-month. View historical data for Supernus Pharmaceuticals and its competitors. Supernus Pharmaceuticals's current YoY EPS Growth is -352.50%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Supernus Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Supernus Pharmaceuticals (LTS:0LB2) is currently considered Fairly Valued. The stock's GF Value™ is $43.67, compared to a current price of $41.45 — trading 5.1% below its estimated fair value. The current YoY EPS Growth is -352.50%. Supernus Pharmaceuticals' overall GF Score™ is 85/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is YoY EPS Growth calculated?
YoY EPS Growth is calculated from a company's financial statements. For Supernus Pharmaceuticals (LTS:0LB2), the current YoY EPS Growth is -352.50% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Supernus Pharmaceuticals (LTS:0LB2) Overvalued in 2026?

Based on GuruFocus' analysis, Supernus Pharmaceuticals stock appears to be undervalued. The current stock price of $41.45 is trading 5.1% below its estimated GF Value™ of $43.67. GuruFocus considers Supernus Pharmaceuticals to be Fairly Valued.

Key valuation signals for LTS:0LB2:

  • YoY EPS Growth: -352.50%
  • GF Value™: $43.67 vs. price of $41.45 (5.1% below fair value)
  • GF Score™: 85/100 with 1 warning sign

No single metric tells the full story. See the LTS:0LB2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Supernus Pharmaceuticals Business Description

Other Exchanges SUPN:USAS49:Germany
Address 9715 Key West Avenue, Rockville, MD, USA, 20850
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, Osmolex ER, and others.
85GF Score

Get the complete analysis for LTS:0LB2

YoY EPS Growth is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$41.45
Price
$43.67
GF Value